Metagenomi initiated with a Buy at Chardan

Chardan initiated coverage of Metagenomi with a Buy rating and $21 price target. The analyst says the long term potential of the company’s microbial enzyme discovery engine and growing genome editing platforms should enable Metagenomi to match the right editing tool for the job to address an array of disease types. The firm views Metagenomi as an attractive option for broad exposure to the genome editing space over the coming years.